Tag: SGLT2 inhibitors
-
Jardiance Might Become The Next Blockbuster Diabetes Drug Despite Ketoacidosis And Acute Kidney Injury Side Effects
December 2016 FDA Determination About Cardiovascular Benefits Also Includes Increased Drug Safety Warnings Label Change For Jardiance (Posted by Tom Lamb at DrugInjuryWatch.com) After the December 2, 2016 decision by the FDA…
-
Summer 2016 Update On Diabetes Medicines Invokana / Farxiga / Jardiance: Drug Label Changes And Safety Investigations
According To Drug Regulators, New Possible Side Effects Include: Fatal Cases Of Ketoacidosis; Leg, Foot, And Toe Amputations; And, Lactic Acidosis (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: Invokana “Black-Box Warning” For…
-
Invokana Cases Involving Diabetic Ketoacidosis And Kidney Problems Reported As Adverse Drug Events To FDA
Farxiga, Jardiance, And Other New SLGT2 Diabetes Drugs Also Cause Metabolic Acidosis As Well As Other Serious Side Effects (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE: “Health Canada Warns About Link Between…
-
Atypical Cases Of Diabetic Ketoacidosis (DKA) Associated With Use Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Invokana, Farxiga, And Jardiance
New Drug Safety Announcement By European Medicines Agency (EMA) Intended To Help Minimize Risk Of DKA Side Effect With This Class Of New Diabetes Drugs (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE:…
-
Invokana / Farxiga / Jardiance: New Medical Study Finds A History Of Diabetic Ketoacidosis Events Is Associated With Increased Risk of Death
This Ketoacidosis Side Effect For These New Diabetes Medicines Was The Subject Of A May 2015 FDA Drug Safety Warning Which Was, Perhaps, Not Strong Enough About Dangers (Posted by Tom Lamb at…
-
May 2015 Diabetes Drugs – Ketoacidosis Link Warning By FDA Covers Invokana, Farxiga, And Jardiance, With Label Changes Possible
Case Reports Of These Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Causing Diabetic Ketoacidosis (DKA) Presented At Recent Medical Meeting (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE: “Health Canada Warns About Link Between DKA &…